Summarized by Masters of Longevity from Longevity Technology.
Leqembi Pen coverage explaining a regulatory decision and what this piece will tell readers about a new at-home dosing option for Alzheimer’s care.
Key Takeaways
- Japan approved a subcutaneous autoinjector formulation of the Alzheimer’s antibody for early disease treatment.
- The dosing regimen is two weekly injections totaling 500 mg, designed to match exposure from two-weekly IV dosing.
- Subcutaneous administration showed a generally similar safety profile and fewer systemic injection or infusion reactions.
